Stories
Nifty Pharma Slips 1.6% Amid Profit Booking As Divi's Labs And Sun Pharma Lead Losses
M
Moneycontrol•14-10-2026, 14:57
Nifty Pharma Slips 1.6% Amid Profit Booking As Divi's Labs And Sun Pharma Lead Losses
- •Nifty Pharma index dropped 1.6 percent on October 14, with Divi's Laboratories and Sun Pharma emerging as the top losers.
- •Large-cap pharma companies anticipate weak earnings in the September quarter due to negligible sales of the high-margin cancer drug generic Revlimid.
- •Axis Securities projects a 7 percent year-on-year revenue increase to Rs 40,903 crore, though EBITDA and PAT are expected to decline.
- •Technical analysts note that while the overall structure of Nifty Pharma remains positive, strength is currently driven by stock-specific movements with support seen at 25,400.
Key Questions Answered
The Nifty Pharma index witnessed profit booking on October 14, 2026, falling 1.6% with Divi's Labs and Sun Pharma leading the losses.
Large-cap pharma earnings growth is expected to remain weak due to negligible sales of the high-margin cancer drug generic Revlimid, persistent US pricing pressure, and accelerated spending on R&D, pipeline commercialisation, and new GLP therapy launches.
In Q2FY27, covered Indian pharma companies are expected to report a 7% YoY revenue increase to Rs 40,903 crore, while EBITDA is projected to decline 10% YoY to Rs 8,308 crore and PAT by 19.6% to Rs 4,331 crore.
